Solid-state protein formulations

Therapeutic Delivery

Volumn 6, Issue 1, 2015, Pages 59-82

  Angkawinitwong, Ukrit ^a   Sharma, Garima ^a,b   Khaw, Peng T ^b   Brocchini, Steve ^a,b   Williams, Gareth R ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN DERIVATIVE; PROTEIN;

AMINO ACID SEQUENCE; CONTROLLED DRUG RELEASE; CRYSTALLIZATION; DRUG FORMULATION; EMULSION; FREEZE DRYING; HUMAN; INSULIN RELEASE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; REVIEW; SOLID STATE; SPRAY DRYING; SUSTAINED RELEASE FORMULATION; CHEMISTRY; MEDICINAL CHEMISTRY;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; FREEZE DRYING; PROTEIN STABILITY; PROTEINS;

EID: 84920711952     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.98     Document Type: Review

References (148)

1. Chang BS, Yeung B. Physical stability of protein pharmaceuticals. In: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. Ja meel F, Hershenson S (Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 69-104 (2010).
2. Santucci R, Sinibaldi F, Fiorucci L. Protein folding, unfolding and misfolding: role played by intermediate states. Mini Rev. Med. Chem. 8(1), 57-62 (2008).
3. Creighton T. Protein folding. Biochem. J. 270(1), 1-16 (1990).
4. Dill KA, MacCallum JL. The protein-folding problem, 50 years on. Science 338 (6110), 1042-1046 (2012).
5. Onuchic JN, Wolynes PG. Theory of protein folding. Curr. Opin. Struct. Biol. 14(1), 70-75 (2004).
6. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4(4), 298-306 (2005).
7. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm. Res. 6(11), 903-918 (1989).
8. Ferreira ST, De Felice FG, Chapeaurouge A. Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. Cell Biochem. Biophys. 44(3), 539-548 (2006).
9. Neudecker P, Robustelli P, Cavalli A et al. Structure of an intermediate state in protein folding and aggregation. Science 336(6079), 362-366 (2012).
10. Calamai M, Canale C, Relini A, Stefani M, Chiti F, Dobson CM. Reversal of protein aggregation provides evidence for multiple aggregated States. J. Mol. Biol. 346(2), 603-616 (2005).
11. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm. Res. 27(4), 544-575 (2010).
12. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. Immunogenicity of protein aggregates-concerns and realities. Int. J. Pharm. 431(1-2), 1-11 (2012).
13. Park J, Nagapudi K, Vergara C, Ramachander R, Laurence JS, Krishnan S. Effect of pH and excipients on structure, dynamics, and long-term stability of a model IgG1 monoclonal antibody upon freeze-drying. Pharm. Res. 30(4), 968-984 (2013).
14. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and infuencing factors. Int. J. Pharm. 390(2), 89-99 (2010).
15. Liu L, Braun LJ, Wang W, Randolph TW, Carpenter JF. Freezing-induced perturbation of tertiary structure of a monoclonal antibody. J. Pharm. Sci. 103 (7), 1979-1986 (2014).
16. Li W, Zhou R, Mu Y. Salting effects on protein components in aqueous NaCl and urea solutions: toward understanding of urea-induced protein denaturation. J. Phys. Chem. B. 116 (4), 1446-1451 (2012).
17. Monera OD, Kay CM, Hodges RS. Protein denaturation with guanidine hydrochloride or urea provides a different estimate of stability depending on the contributions of electrostatic interactions. Protein Sci. 3(11), 1984-1991 (1994).
18. Mahler H-C, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98(9), 2909-2934 (2009).
19. Liu J, Nguyen MDH, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci. 94 (9), 1928-1940 (2005).
20. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289(1-2), 1-30 (2005).
21. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21(6), 897-903 (2004).
22. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 8(3), E501-E507 (2006).
23. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81(11), 678-699 (2003).
24. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv. Drug Deliv. Rev. 63(13), 1118-1159 (2011).
25. Jeong SH. Analytical methods and formulation factors to enhance protein stability in solution. Arch. Pharm. Res. 35(11), 1871-1886 (2012).
26. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci. 100(10), 4171-4197 (2011).
27. Krishnan S, Pallitto M, Ricci M. Development of formulations for therapeutic monoclonal antibodies and Fc fusion proteins. In: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. Jameel F, Hershenson S (Eds.). John Wiley & Sons Inc., Hoboken, NJ, USA, 383-428 (2010).
28. Sundaramurthi P, Suryanarayanan R. Calorimetry and complementary techniques to characterize frozen and freeze-dried systems. Adv. Drug Deliv. Rev. 64(5), 384-395 (2012).
29. Topp EM, Zhang L, Zhao H, Payne RW, Evans GJ, Manning MC. Chemical instability in peptide and protein pharmaceuticals. In: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. Jameel F, Hershenson S (Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 41-67 (2010).
30. Andya JD, Hsu CC, Shire SJ. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci. 5(2), 21-31 (2003).
31. Franks F. Freeze-drying of bioproducts: putting principles into practice. Eur. J. Pharm. Biopharm. 45(3), 221-229 (1998).
32. Carpenter JF, Pikal MJ, Chang BS, Randolph TW Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14(8), 969-975 (1997).
33. Gaisford S, Saunders M. Physical forms I-Crystalline materials. In: Essentials of Pharmaceutical Preformulation. John Wiley & Sons Inc., West Sussex, 127-155 (2013).
34. Shenoy B, Wang Y, Shan W, Margolin AL. Stability of crystalline proteins. Biotechnol. Bioeng. 73(5), 358-369 (2001).
35. Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4(3), 301-317 (2004).
36. Chayen NE, Saridakis E. Protein crystallization: from purifed protein to diffraction-quality crystal. Nat. Method. 5(2), 147-153 (2008).
37. Feher G, Kam Z. Nucleation and growth of protein crystals: general principles and assays. Methods Enzymol. 114, 77-112 (1985).
38. Bertrand G, Macheboeuf M. The infuence of nickel and cobalt on the effect exerted by insulin in a rabbit. Science 64, 629-630 (1926).
39. Lutz RE. The normal occurrence of zinc in biologic materials: a review of the literature, and a study of the normal distribution of zinc in the rat, cat, and man. J. Ind. Hygiene 8, 177 (1926).
40. Baker E, Blundell T, Cutfeld J et al. The structure of 2Zn pig insulin crystals at 1.5 A resolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 319, 369-456 (1988).
41. Smith G, Pangborn W, Blessing R. The structure of T6 human insulin at 1.0 A resolution. Acta Crystallogr. Sect. D Biol. Crystallogr. 59, 474-482 (2003).
42. Whittingham JL, Chaudhuri S, Dodson EJ, Moody PC, Dodson GG. X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agenst, thiocyanate, methylparaben and phenol. Biochemistry 34, 15553-15563 (1995).
43. Smith GD, Dodson GG. Structure of a rhombohedral R6 insulin/phenol complex. Proteins 14, 401-408 (1992).
44. Shi K, Bi H, Jiang Y. Characterization of physiochemical and biological properties of spherical protein crystals for sustained release. Asian J. Pharm. Sci. 8(1), 58-63 (2013).
45. Hebel D, Huber S, Stanislawski B, Hekmat D. Stirred batch crystallization of a therapeutic antibody fragment. J. Biotechnol. 166, 206-211 (2013).
46. Nanev CN. How do crystal lattice contacts reveal protein crystallization mechanism? Cryst. Res. Technol. 43(9), 914-920 (2008).
47. Nanev CN. Protein crystal nucleation: Recent notions. Cryst. Res. Technol. 42(1), 4-12 (2007).
48. Northrup SH, Erickson HP. Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc. Natl Acad. Sci. USA 89(8), 3338-3342 (1992).
49. Wukovitz S, Yeates T Why protein crystals favour some space-groups over others. Nat. Struc. Biol. 2, 1062-1067 (1995).
50. Nanev CN. Protein crystal nucleation: Recent notions. Crystal Res. Tech. 12(1), 4-12 (2007).
51. Nanev CN. Kinetics and intimate mechanism of protein crystal nucleation. Prog. Cryst. Growth Charact. Mater. 59(4), 133-169 (2013).
52. Huus K, Havelund S, Olsen HB, van de Wert M, Frokjaer S. Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer. Pharm. Res. 23(11), 2611-2620 (2006).
53. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 358(9283), 739-46 (2001).
54. Walsh G. Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol. 67(2), 151-159 (2005).
55. Jonassen I, Havelund S, Jensen T, Steensgaard D, Wahlund P, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104-2114 (2012).
56. Krayenbuhl C, Rosenberg T Crystalline protamine insulin. Rep. Steno. Mem. Hosp. Nord. Insul. 1, 60-73 (1946).
57. Hoffmann J, Chance R, Johnson M. Purifcation and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Protein Expr. Purif. 1(2), 127-133 (1990).
58. Balschimidt P, Hansen F, Dodson E, Dodson G, Kober F. Structure of porcine insulin cocrystallized with clupeine-z. Acta Crystallogr. B 47, 975-986 (1991).
59. Norrman M, Hubálek F, Schluckebier G. Structural characterization of insulin NPH formulations. Eur. J. Pharm. Sci. 30(5), 414-423 (2007).
60. Hirsch I. Insulin analogues. N. Engl. J. Med. 352, 174-183 (2005).
61. Barnett A, Owens D. Insulin analogues. Lancet 349 (9044), 47-51 (1997).
62. Gough SCL, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes. O bes. Metab. 15(4), 301-309 (2013).
63. Jameel F, Pikal M. Design of a formulation for freeze drying. In: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. Jameel F, Hershenson S (Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 457-492 (2010).
64. Cheung MS, García AE, Onuchic JN. Protein folding mediated by solvation: water expulsion and formation of the hydrophobic core occur after the structural collapse. Proc. Natl Acad. Sci. USA 99(2), 685-690 (2002).
65. Crommelin DJ. Formulation of biotech products, including biopharmaceutical considerations. In: Pharmaceutical Biotechnology. Crommelin DJA, Sindelar RD, Meibohm B (Eds.). Springer, New York, USA, 67-123 (2008).
66. Kasper JC, Friess W. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm. 78(2), 248-63 (2011).
67. Wang W Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203(1-2), 1-60 (2000).
68. Heller MC, Carpenter JF, Randolph TW Protein formulation and lyophilization cycle design: Prevention of damage due to freeze-concentration induced phase separation. Biotechnol. Bioeng. 63(2), 166-174 (1999).
69. Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm. Res. 21(2), 191-200 (2004).
70. Colandene JD, Maldonado LM, Creagh AT, Vrettos JS, Goad KG, Spitznagel TM. Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent. J. Pharm. Sci. 96(6), 1598-1608 (2007).
71. Franks F, Auffret T. Freeze-drying of pharmaceuticals and biopharmaceuticals: Principles and Practice. Royal Society of Chemistry, London, UK (2007).
72. Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J. Pharm. Sci. 98(9), 2886-2908 (2009).
73. Eckhardt BM, Oeswein JQ, Bewley TA. Effect of freezing on aggregation of human growth hormone. Pharm. Res. 8(11), 1360-1364 (1991).
74. Strambini GB, Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys. J. 70(2), 971-976 (1996).
75. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol. 12(5), 505-523 (2007).
76. Ohtake S, Kita Y, Arakawa T. Interactions of formulation excipients with proteins in solution and in the dried state. Adv. Drug Deliv. Rev. 63(13), 1053-1073 (2011).
77. Crowe JH, Hoekstra FA, Crowe LM. Anhydrobiosis. Annu. Rev. Physiol. 54(1), 579-599 (1992).
78. Fox K. Biopreservation. Putting proteins under glass. Science 267(5206), 1922-1923 (1995).
79. Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry. 28(9), 3916-3922 (1989).
80. Prestrelski SJ, Arakawa T, Carpenter JF. Separation of freezing-and drying-induced denaturation of lyophilized proteins using stress-specifc stabilization. II. Structural studies using infrared spectroscopy. Arch. Biochem. Biophys. 303(2), 465-473 (1993).
81. Prestrelski SJ, Pikal KA, Arakawa T. Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using Fourier-transform infrared spectroscopy. Pharm. Res. 12(9), 1250-1259 (1995).
82. Nema S, Avis KE. Freeze-thaw studies of a model protein, lactate dehydrogenase, in the presence of cryoprotectants. J. Parenter. Sci. Technol. 47(2), 76-83 (1993).
83. Dawson PJ. Effect of formulation and freeze-drying on the long-term stability of rDNA-derived cytokines. Dev. Biol. Stand. 74, 273-282 (1992).
84. Anchordoquy TJ, Carpenter JF. Polymers protect lactate dehydrogenase during freeze-drying by inhibiting dissociation in the frozen state. Arch. Biochem. Biophys. 332(2), 231-238 (1996).
85. Allison SD, Randolph TW, Manning MC, Middleton K, Davis A, Carpenter JF. Effects of drying methods and additives on structure and function of actin: mechanisms of dehydration-induced damage and its inhibition. Arch. Biochem. Biophys. 358(1), 171-181 (1998).
86. Skrabanja AT, de Meere AL, de Ruiter RA, van den Oetelaar PJ. Lyophilization of biotechnology products. PDA J. Pharm. Sci. Technol. 48 (6), 311-317 (1994).
87. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch. Biochem. Biophys. 360(1), 121-134 (1998).
88. Izutsu K-I, Yoshioka S, Kojima S. Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices. Pharm. Res. 12(6), 838-843 (1995).
89. Carpenter JF, Prestrelski SJ, Arakawa T. Separation of freezing-and drying-induced denaturation of lyophilized proteins using stress-specifc stabilization: I. Enzyme activity and calorimetric studies. Arch. Biochem. Biophys. 303(2), 456-464 (1993).
90. Bhatnagar BS, Martin SM, Teagarden DL, Shalaev EY, Suryanarayanan R. Investigation of PEG crystallization in frozen PEG-sucrose-water solutions: II. Characterization of the equilibrium behavior during freeze-thawing. J. Pharm. Sci. 99 (11), 4510-4524 (2010).
91. Jameel F, Hershenson S. Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals (1st Edition). John Wiley & Sons Inc., Hoboken, NJ, USA (2010).
92. Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci. 85(12), 1325-1330 (1996).
93. Mumenthaler M, Hsu CC, Pearlman R. Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res. 11(1), 12-20 (1994).
94. Pikal-Cleland KA, Rodríguez-Hornedo N, Amidon GL, Carpenter JF. Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric β-galactosidase. Arch. Biochem. Biophys. 384(2), 398-406 (2000).
95. Pikal-Cleland KA, Carpenter JF. Lyophilization-induced protein denaturation in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. J. Pharm. Sci. 90(9), 1255-1268 (2001).
96. Pikal-Cleland KA, Cleland JL, Anchordoquy TJ, Carpenter JF. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J. Pharm. Sci. 91(9), 1969-1979 (2002).
97. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J. Pharm. Sci. 96(1), 1-26 (2006).
98. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10(4), 307-377 (1993).
99. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 58(5-6), 686-706 (2006).
100. Chang LL, Shepherd D, Sun J et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specifc interaction, and/or immobilization in a glassy matrix? J. Pharm. Sci. 94(7), 1427-1444 (2005).
101. Campos E, Branquinho J, Carreira AS, Carvalho A, Coimbra P, Ferreira C. Designing polymeric microparticles for biomedical and industrial applications. European Polymer Journal 49(8), 2005-2021 (2013).
102. Abdul-Fattah AM, Kalonia DS, Pikal MJ. The challenge of drying method selection for protein pharmaceuticals: product quality implications. J. Pharm. Sci. 96 (8), 1886-1916 (2007).
103. Prinn K, Constantino HR, Tracy M. Statistical modeling of protein spray drying at the lab scale. AAPS PharmSciTech. 3(1) (2002).
104. Ståhl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int. J. Pharm. 233, 227-237 (2002).
105. Banga A. Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems (2nd Edition).CRC Press, FL (2006).
106. Abdul-Fattah AM, Lechuga-Ballesteros D, Kalonia DS, Pikal MJ. The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state. J. Pharm. Sci. 97(1), 163-184 (2008).
107. Ananthapadmanabhan K. Protein-surfactant interactions. Interact Surfactants Polym. Proteins. 319-365 (1993).
108. Costantino HR, Andya JD, Nguyen PA et al. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 87(11), 1406-1411 (1998).
109. Grohganz H, Lee Y-Y, Rantanen J, Yang M. The infuence of lysozyme on mannitol polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying process. Int. J. Pharm. 447(1-2), 224-230 (2013).
110. Hill JJ, Shalaev EY, Zograf G. Thermodynamic and dynamic factors involved in the stability of native protein structure in amorphous solids in relation to levels of hydration. J. Pharm. Sci. 94 (8), 1636-1667 (2005).
111. Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin. G Eur. J. Pharm. Biopharm. 59(2), 251-261 (2005).
112. Liao Y-H, Brown MB, Nazir T, Quader A, Martin GP. Effect of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme. Pharm. Res. 19 (12), 1847-1853 (2002).
113. Sou T, Kaminskas LM, Nguyen T-H, Carlberg R, McIntosh MP, Morton DA. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm. 83, 234-243 (2012).
114. Abdul-Fattah AM, Truong-le VU, Yee L et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody. J. Pharm. Sci. 96(8), 1983-2008 (2008).
115. Chan HK. Dry powder aerosol drug delivery-Opportunities for colloid and surface scientists. Colloids Surf. A Physicochem. Eng. Asp. 284-285, 50-55 (2006).
116. Shoyele S a, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev. 58(9-10), 1009-1029 (2006).
117. Ogáin ON, Li J, Tajber L, Corrigan OI, Healy AM. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffnose) for protein delivery. Int. J. Pharm. 405(1-2), 23-35 (2011).
118. Bosquillon C, Rouxhet PG, Ahimou F et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 99(3), 357-367 (2004).
119. White S, Bennett DB, Cheu S et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 7(6), 896-906 (2005).
120. Heinemann L. The failure of exubera: are we beating a dead horse? J. Diabetes Sci. Technol. 2(3), 518-29 ( 2008).
121. Mannkind Corporation. Delivery & device technology for inhalation medicines & therapy www.mannkindtechnologies.com.
122. Taluja A, Youn YS, Bae YH. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. J. Mater. Chem. 17(38), 4002 (2007).
123. Yuan W, Wu F, Guo M, Jin T. Development of protein delivery microsphere system by a novel s/o/o/w multi-emulsion. Eur. J. Pharm. Sci. 36, 212-218 (2009).
124. Rosca ID, Watari F, Uo M. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J. Control. Release 99(2), 271-280 (2004).
125. Grabnar PA, Kristl J. The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers. J. Microencapsul. 28(4), 323-35 (2011).
126. Jovanovi N, Bouchard A, Hofand GW, Witkamp G-J, Crommelin DJA, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fuid technology. Pharm. Res. 21(11), 1955-1969 (2004).
127. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery J. Control. Release 90(3), 261-280 (2003).
128. Li X, Kong X, Shi S et al. Preparation of alginate coated chitosan microparticles for vaccine delivery BMC Biotechnol. 8(89) (2008).
129. Grenha A, Rodrigues S. Pullulan-based nano particles: future therapeutic applications in transmucosal protein delivery Ther. Deliv. 4(11), 1339-1341 (2013).
130. Kim S, Hahn S, Kim M, Kim D, Lee Y. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control. Release. 104(2), 323-335 (2005).
131. Lee ES, Park K-H, Kang D et al. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres. Biomaterials 28(17), 2754-2762 (2007).
132. Hu L, Zhang H, Song W An overview of preparation and evaluation sustained-release injectable microspheres. J. Microencapsul. 30(4), 369-382 (2013).
133. Mao S, Guo C, Shi Y, Li LC. Recent advances in polymeric microspheres for parenteral drug delivery-part 1. Expert Opin. Drug Deliv. 9(9), 1161-1176 (2012).
134. Emami J, Hamishehkar H, Najafabadi AR et al. A novel approach to prepare insulin-loaded poly(lactic-co-glycolic acid) microcapsules and the protein stability study J. Pharm. Sci. 98(5), 1712-1731 (2009).
135. Raf M, Singh SM, Kanchan V, Anish CK, Panda AK. Controlled release of bioactive recombinant human growth hormone from PLGA microparticles. J. Microencapsul. 27(6), 552-560 (2010).
136. Bilati U, Allémann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano-and microparticles. Eur. J. Pharm. Biopharm. 59(3), 375-388 (2005).
137. Cawley P, Wilkinson I, Ross RJ. Developing long-acting growth hormone formulations. Clin. Endocrinol. (Oxf). 79(3), 305-309 (2013).
138. Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28(1), 43-70 (1997).
139. Miller RA, Brady JM, Cutright DE. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modifcation with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 11(5), 711-719 (1977).
140. Williams GR, Chatterton NP, Nazir T, Yu D-G, Zhu L-M, Brandford-White CJ. Electrospun nanofbers in drug delivery: recent developments and perspectives. Ther. Deliv., 515-533 (2012).
141. Jia H, Zhu G, Vugrinovich B, Kataphinan W, Reneker DH, Wang P. Enzyme-carrying polymeric nanofbers prepared via electrospinning for use as unique biocatalysts. Biotechnol. Prog. 18(5), 1027-1032 (2002).
142. Jiang H, Hu Y, Li Y, Zhao P, Zhu K, Chen W. A facile technique to prepare biodegradable coaxial electrospun nanofbers for controlled release of bioactive agents. J. Control. Release 108(2-3), 237-243 (2005).
143. Yang Y, Li X, Cui W, Zhou S, Tan R, Wang C. Structural stability and release profles of proteins from core-shell poly (DL-lactide) ultrafne fbers prepared by emulsion electrospinning. J. Biomed. Mater. Res. A. 86(2), 374-385 (2008).
144. Ahmad B, Gunduz O, Stoyanov S, Pelan E, Stride E, Edirisinghe M. A novel hybrid system for the fabrication of a fbrous mesh with micro-inclusions. Carbohydr. Polym. 89(1), 222-229 (2012).
145. Jia X, Zhao C, Li P et al. Sustained release of VEGF by coaxial electrospun dextran/PLGA fbrous membranes in vascular tissue engineering. J. Biomater. Sci. Polym. Ed. 22(13), 1811-1827 (2011).
146. Khalili H, Godwin A, Choi J-W, Lever R, Khaw PT, Brocchini S. Fab-PEG-Fab as a potential antibody mimetic. Bioconjug. Chem. 24(11), 1870-1882 (2013).
147. Rifkin RA, Maggio ET, Dike S, Kerr DA, Levy M. n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J. Neuroimmune Pharmacol. 6(1), 158-162 (2011).
148. Creative Commons license. Http://creativecommons.org/licenses/by-nc-nd/3.0/